DDW Editor Reece Armstrong speaks to Yerem Yeghiazarians, CEO and Co-Founder of Soley Therapeutics, about the limitations of current assays and how the company’s live cell approach can improve drug discovery.   RA: What are the current limitations of static assays and single endpoints in assessing how cells respond to drugs? YY: Most conventional assays provide a static snapshot of a process […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!